Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
IPO Year: 2019
Exchange: NASDAQ
Website: brainsway.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2023 | Outperform → Mkt Perform | Raymond James | |
| 3/3/2022 | $15.00 | Buy | Loop Capital |
| 11/29/2021 | $14.00 → $15.00 | Buy | HC Wainwright & Co. |
| 8/12/2021 | $17.00 → $14.00 | Buy | HC Wainwright & Co. |
| 7/19/2021 | $17.00 | Buy | HC Wainwright & Co. |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Raymond James downgraded Brainsway from Outperform to Mkt Perform
Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00
HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously
HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $14.00 from $17.00 previously
HC Wainwright & Co. initiated coverage of BrainsWay with a rating of Buy and set a new price target of $17.00
Northland Capital initiated coverage of Brainsway with a rating of Outperform and set a new price target of $15.00
Oppenheimer reiterated coverage of Brainsway with a rating of Outperform and set a new price target of $15.00 from $13.00 previously
Raymond James reiterated coverage of Brainsway with a rating of Outperform and set a new price target of $12.00 from $9.00 previously
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
424B3 - Brainsway Ltd. (0001505065) (Filer)
EFFECT - Brainsway Ltd. (0001505065) (Filer)
F-3 - Brainsway Ltd. (0001505065) (Filer)
20-F - Brainsway Ltd. (0001505065) (Filer)
Fastest customizable press release news feed in the world
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported second quarter 2025 financial results and provided an operational update. Recent Financial and
BURLINGTON, Mass. and JERUSALEM, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay, a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its underwriting of two new Continuing Medical Education (CME) courses designed to expand clinician knowledge and confidence in the use of Transcranial Magnetic Stimulation (TMS). These online, no-cost CME activities aim to deepen understanding of the robust clinical evidence supporting TMS, clarify distinctions between Deep TMS™—a proprietary BrainsWay technology—and first-generation figure-8 coil TMS, and provide practical guidance for integrating TMS into clinical practice. Supported t
BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, August 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300-85
BURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced preliminary results from a multicenter, randomized controlled trial titled, "Accelerated Deep TMS for Depression: Results from a Multisite, Randomized Non-Inferiority Trial." The results suggest that the accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol using intermittent theta burst stimulation (iTBS) to treat patients with major depressive disorder (MDD) resulted in outcomes that are comparable to the standard once-daily TMS protocol — while requiring
BURLINGTON, Mass. and JERUSALEM, June 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with Stella MSO, LLC ("Stella Mental Health" or "Stella"), a management services organization servicing more than 20 mental health clinics across the U.S. and Israel that have treated over 30,000 patients to date. "Our investment in Stella Mental Health is just the first of the minority-stake investments we are planning to make in high-performing providers across the U.S. These equity i
Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a record net number of Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Company is reiterating its full-year 2025 financial guidance, including revenue of $49 to $51 million, operating profit of 3% to 4% and Adjusted EBITDA of 11% to 12% Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 13, 2025 (GLOBE NEWSWIRE) --
BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California. As part of the meeting's educational programming, there will be a full day master course on Sunday, May 18, 2025, entitled: "Clinical Applications for Psychiatric Practice: Ketamine and TMS." The course will provide an in-depth look at the integration of novel treatments into clinical psychiatric practice, highlighting practical approa
BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300
Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua
BURLINGTON, Mass. and JERUSALEM, March 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present virtually at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference at 9:20 AM EST on March 18, 2025. A live webcast of the presentation will be available on the Events & News – Presentations page of the Company's Investor Relations website. An archived replay of the presentation will be available on the Company's website for 30 days following the live broadcast. Please contact your representativ
This live feed shows all institutional transactions in real time.
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13D - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
Live finance-specific insights
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported second quarter 2025 financial results and provided an operational update. Recent Financial and
BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, August 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300-85
Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a record net number of Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Company is reiterating its full-year 2025 financial guidance, including revenue of $49 to $51 million, operating profit of 3% to 4% and Adjusted EBITDA of 11% to 12% Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 13, 2025 (GLOBE NEWSWIRE) --
BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300
Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua
BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2024 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, March 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, March 11, 2025Time:8:30 AM Eastern TimeUnited
Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported third quarter 2024 financial results and provided an operational update. Recent Financial and Operational Highlights For the three months ended September 30, 2024, revenues were $10.5 million, a 26% increase compared to the same period in 202
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, November 12, 2024Time:8:30 AM Eastern TimeUnited States:1-877-300-8521I
Generated Robust 28% Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Fourth Consecutive Quarter Raising Lower End of Full-Year 2024 Revenue Guidance to Range of $38.5 Million to $40 Million Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported second quarter 2024 financial results and provided an operational update. Recent F
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information: Date: Tuesday, August 6, 2024Time:8:30 AM Eastern TimeUnited States:1-877-300-8521Inte
Live Leadership Updates
BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys
Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO). Mr. Marom will succeed Scott Areglado, who will be stepping down from the Company to pursue other opportunities. "We are thrilled to welcome Ido and his extensive financial expertise to BrainsWay," stated Hadar Levy, BrainsWay's Chief Executive Officer. "He has led the financial strategy and i
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Hadar Levy, the Company's Senior Vice President (SVP) and Chief Operating Officer (COO), and a member of BrainsWay's senior leadership team since 2014, as Chief Executive Officer (CEO). Mr. Levy has been instrumental as a sales, financial and operational leader for the Company throughout his tenure at BrainsWay, previously serving as the Company's Chief Financial Officer and then General Manager North America, before assuming
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ami Boehm, as Chairman of the Board. David Zacut, M.D., co-founder of BrainsWay, who has held the role of Chairman since the Company's inception, will now serve as a Director on the Board. "It has been very satisfying to have supported BrainsWay's evolution from a nascent R&D start-up to a world-class commercial company offering the industry's leading TMS technology and solution," stated Dr. Zacut. "After 19 intensive years,
BURLINGTON, Mass. and JERUSALEM, Nov. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Colleen A. Hanlon, Ph.D. as Vice President of Medical Affairs. Formerly a professor at Wake Forest University School of Medicine and a member of the Wake Forest Center for Addiction Research, Dr. Hanlon brings nearly 20 years of experience in the field of brain imaging and brain stimulation research. At BrainsWay, she will drive the integration of medical and scientific intelligence to inform TMS providers on state-of-the art
BURLINGTON, Mass. and JERUSALEM, May 09, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Eric Hirt as Vice President of U.S. Sales. Mr. Hirt has more than 20 years of experience in the medical device industry. He will be responsible for all U.S. sales and marketing activities for the Company's Deep Transcranial Magnetic Stimulation (Deep TMS™) system. "Eric brings more than 20 years of experience in medical device sales and marketing to BrainsWay. He has successfully created and implemented sales and marketing str
BURLINGTON, Mass. and JERUSALEM, March 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Joachim "Joe" Seidel, Ph.D., to the newly created position of Vice President of Corporate Development and Strategy. Dr. Seidel has more than 20 years of experience in the medical device industry and has held positions in business development, corporate strategy, program management, and research and development. He will be responsible for pursuing strategic opportunities for BrainsWay and overseeing its global corporate develo
CRESSKILL, N.J. and JERUSALEM, May 05, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer effective today. "We are very pleased to announce that Scott Areglado has joined BrainsWay to become our Senior Vice President and Chief Financial Officer," stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. "Scott's appointment comes at a critically important time for our company, as we expand our commercial operation